Amgen Raises 2026 Revenue and Profit Guidance Following Q3 Earnings Beat
Amgen (AMGN) has upwardly revised its financial guidance for the year 2026 following a third-quarter earnings report that exceeded analyst expectations for both revenue and profit. The company's updated full-year revenue projection now sits between $38.9 billion and $39.7 billion, surpassing previous estimates. In addition to top-line growth, Amgen raised its non-GAAP earnings per share (EPS) guidance to a range of $22.90 to $23.70. This revision reflects strong operational performance and provides a more optimistic outlook for the company's long-term profitability compared to prior forecasts.
Tickers: $AMGN